Dr. Kurt Stoeckli is President and Chief Scientific Officer of Glenmark Pharmaceuticals Ltd., based in Neuchâtel, Switzerland. He oversees global research and early development of innovative products including new biological entities and new chemical entities, with operations in Switzerland, U.S. and India. He also manages both the generics and branded formulations research. Dr. Stoeckli brings more than 25 years of experience in the global life sciences industry where he focused on biopharmaceutical research and development. Prior to joining Glenmark Pharmaceuticals in 2016, Dr. Stoeckli assumed executive roles at SANOFI, first as global therapeutic area head of immunology and inflammation, and most recently as Group Vice President for the Global Biotherapeutics Division, based in Paris.
Dr. Stoeckli first joined industry in 1993 with Novartis in Basel, Switzerland where he held positions of increasing leadership and provided global support for all biomedical research activities at the Novartis Lead Discovery Center. An immunologist and chemist by training, he graduated from the University of Basel, ETH Zurich and the Max-Planck-Institute for Neurobiology in Munich where he received his PhD in Molecular Cell Biology. Dr. Stoeckli has been a Postdoctoral Fellow & Assistant Professor in the Department of Biochemistry & Biophysics, University of California Medical Center.